dc.contributor.author | Ozdemir, O | |
dc.contributor.author | Zengel, B | |
dc.contributor.author | Yildiz, Y | |
dc.contributor.author | Uluc, BO | |
dc.contributor.author | Cabuk, D | |
dc.contributor.author | Ozden, E | |
dc.contributor.author | Salim, DK | |
dc.contributor.author | Paydas, S | |
dc.contributor.author | Demir, A | |
dc.contributor.author | Diker, O | |
dc.contributor.author | Pilanci, KN | |
dc.contributor.author | Sonmez, OU | |
dc.contributor.author | Vatansever, S | |
dc.contributor.author | Dogan, I | |
dc.contributor.author | Gulmez, A | |
dc.contributor.author | Cakar, B | |
dc.contributor.author | Gursoy, P | |
dc.contributor.author | Yildirim, ME | |
dc.contributor.author | Ayhan, M | |
dc.contributor.author | Karadurmus, N | |
dc.contributor.author | Aykan, MB | |
dc.contributor.author | Cevik, GT | |
dc.contributor.author | Sakalar, T | |
dc.contributor.author | Hacibekiroglu, I | |
dc.contributor.author | Gulbagci, BB | |
dc.contributor.author | Dincer, M | |
dc.contributor.author | Garbioglu, DB | |
dc.contributor.author | Kemal, Y | |
dc.contributor.author | Nayir, E | |
dc.contributor.author | Taskaynatan, H | |
dc.contributor.author | Yilmaz, M | |
dc.contributor.author | Avci, O | |
dc.contributor.author | Sari, M | |
dc.contributor.author | Coban, E | |
dc.contributor.author | Atci, MM | |
dc.contributor.author | Esen, SA | |
dc.contributor.author | Telli, TA | |
dc.contributor.author | Karatas, F | |
dc.contributor.author | Inal, A | |
dc.contributor.author | Demir, H | |
dc.contributor.author | Kalkan, NO | |
dc.contributor.author | Yilmaz, C | |
dc.contributor.author | Tasli, F | |
dc.contributor.author | Alacacioglu, A | |
dc.date.accessioned | 2023-01-02T08:53:10Z | |
dc.date.available | 2023-01-02T08:53:10Z | |
dc.date.issued | 2022 | |
dc.identifier.uri | http://hdl.handle.net/11616/86973 | |
dc.description.abstract | In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group (TOG) with data collected from 32 centers. Our study was multicentric, and a total of 364 patients were included. The median age of the patients was 49 years (18-85 years). Two hundred fifteen (60%) of the cases were hormone receptor/HER2+ positive(ER+ or PR+, or both), and 149 (40%) of them were HER2-rich (ER and PR negative). The number of complete responses was 124 (54%) in the docetaxel+trastuzumab+pertuzumab arm and 102 (45%) in the paclitaxel+trastuzumab+pertuzumab arm, and there was no difference between the groups in terms of complete response. In 226 (62%) patients with complete response, a significant correlation was found with DCIS, tumor focality, removed lymph node, and ER status P < 0.05. Anemia, nausea, vomiting, myalgia, alopecia, and mucosal inflammation were significantly higher in the docetaxel arm, P < 0.05. In our study, no statistical difference was found between the before-after echocardiography values. DCIS positivity in biopsy before neoadjuvant chemotherapy, tumor focality; the number of lymph nodes removed and ER status were found to be associated with pCR. In conclusion, we think that studies evaluating pCR-related clinicopathological variables and radiological imaging features will play a critical role in the development of nonsurgical treatment approaches. | |
dc.source | ANTI-CANCER DRUGS | |
dc.title | The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab | |
dc.title | in women with locally advanced, inflammatory, or early-stage human | |
dc.title | epidermal growth factor receptor 2-positive breast cancer: Turkish | |
dc.title | Oncology Group study |
Dosyalar | Boyut | Biçim | Göster |
---|---|---|---|
Bu öğe ile ilişkili dosya yok. |